Clinical trials: Phase 2, completed
Obesity or Overweight
A Study Evaluating the Effect of Daily Oral RO7795081 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity
This multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-range-finding, Phase II study aims to evaluate the efficacy, tolerability, and safety of RO7795081 for chronic weight management in adult…
- Trial name
- NCT07081958
- Testing
- RO7795081
- Where
- 36 sites in United States
- Volunteers
- 352 people
- Sponsor
- Hoffmann-La Roche
Acute Heart Failure
Assessing the Clinical Outcomes of Dapagliflozin Versus Acetazolamide in Patients With Acute Heart Failure
This study investigates the comparative clinical outcomes of dapagliflozin, an SGLT-2 inhibitor, versus acetazolamide, a carbonic anhydrase inhibitor, in patients hospitalized with acute heart failure (AHF).
- Trial name
- NCT06783166
- Testing
- Dapagliflozin 10mg, Acetazolamide 500mg
- Where
- Egypt
- Volunteers
- 108 people
- Sponsor
- Mansoura University
Pneumonia, Sepsis
Effects of Lumbrokinase DLBS1033 on D-Dimer, Interleukin-6, and Clinical Outcomes in Patients With Pneumonia and Sepsis
Pneumonia is a lung infection that can cause serious complications, especially when accompanied by sepsis. Sepsis can trigger excessive inflammation and abnormal blood clotting, potentially leading to organ damage and delayed…
- Conditions
- Pneumonia, Sepsis, Blood Coagulation Disorders
- Trial name
- NCT07892794
- Testing
- DLBS1033
- Where
- Indonesia
- Volunteers
- 50 people
- Sponsor
- Universitas Sebelas Maret
Knee Osteoarthritis, Synovitis of Knee
A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis
This phase 2a trial is an international, multicenter, randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of one single intra-articular (IA) injection of 4P004 or placebo in: patients between…
- Trial name
- INFLAM MOTION (NCT07225829)
- Testing
- 4P004
- Where
- 22 sites in United States, Canada and 4 more
- Volunteers
- 130 people
- Sponsor
- 4Moving Biotech
Osteopenia, Osteoporosis, Age-related Bone Loss
Senolytics to Improve Osteoporosis Therapy
This randomised clinical trial aims to study osteoporosis as a disease of accelerated skeletal aging caused by the accumulation of senescent cells within the skeleton and investigate the effects and safety of senolytics and…
- Trial name
- SENIOR (NCT06018467)
- Testing
- Dasatinib 100 Mg Oral Tablet, Quercetin 1.250 mg (oral), Nicotinamide Riboside 1g (oral)
- Where
- Denmark
- Volunteers
- 120 people
- Sponsor
- Odense University Hospital
Pleural Infection
Trial of Reduced Alteplase Dose for Parapneumonic Effusion (TRAPPE)
Objectives: A pilot study to assess the feasibility of a randomization trial protocol comparing low (2.5mg) and standard (10mg) doses of intrapleural tissue plasminogen activator (tPA) with deoxyribonucleases (DNase) in…
- Trial name
- NCT05766124
- Testing
- Tissue Plasminogen Activator
- Where
- 2 sites in Hong Kong
- Volunteers
- 30 people
- Sponsor
- Chinese University of Hong Kong
Psoriasis (PsO)
A Phase 2 Study of HB0017 in Psoriasis Patients
This study is a randomized, double-blind phase 2 clinical trial aimed at exploring the efficacy, safety, and immunogenicity of HB0017 injection with different dosing regimens in the treatment of moderate to severe plaque…
- Trial name
- HB0017 (NCT06592274)
- Testing
- HB0017
- Where
- 18 sites in China
- Volunteers
- 206 people
- Sponsor
- Huabo Biopharm Co., Ltd.
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer
This phase I/II trial studies the best dose of selumetinib and how well it works with durvalumab and tremelimumab in treating participants with stage IV non-small cell lung cancer or that has come back.
- Conditions
- Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Trial name
- NCT03581487
- Testing
- Durvalumab, Selumetinib, Tremelimumab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Heart Failure With Preserved Ejection Fraction
Efficacy and Safety of Qishenyiqi Dripping Pills for Treating Chronic Heart Failure With Preserved Ejection Fraction
Main objective: To evaluate the efficacy, safety and clinical dose exploration of Qishen Yiqi dripping pills in the treatment of chronic heart failure with preserved ejection fraction.
- Trial name
- NCT04944706
- Testing
- Qishen Yiqi dripping pills 4 bags/time
- Where
- 16 sites in China
- Volunteers
- 225 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Norovirus Acute Gastroenteritis
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age
The purpose of the Part A Phase 1 of this study is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1403 and mRNA-1405 in healthy adult participants 18 to 49 years of age and 60 to 80 years of age.
- Trial name
- NCT05992935
- Testing
- mRNA-1403, mRNA-1405
- Where
- 16 sites in United States, Australia
- Volunteers
- 1,407 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Hodgkin Lymphoma
Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma
Limited stage Hodgkin lymphoma is a highly curable disease, but standard treatment with ABVD chemotherapy and radiation can lead to late risks of secondary cancers, lung injury, heart injury, and others.
- Trial name
- NCT02505269
- Testing
- Brentuximab Vedotin, Adriamycin, Dacarbazine
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- Massachusetts General Hospital
Chronic Heart Failure With Reduced Ejection Fraction
Efficacy and Safety of QiShen YiQi Dripping Pills in Chronic Heart Failure
This study will evaluate the efficacy and safety and the best effective dose of QiShen YiQi Dripping Pills in the treatment of chronic heart failure with decreased ejection fraction of CHD (Qi deficiency and blood stasis…
- Trial name
- NCT04983043
- Testing
- Low dose QiShen YiQi Dripping Pills 3 bags, High dose QiShen YiQi Dripping Pills 3 bags
- Where
- 23 sites in China
- Volunteers
- 228 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Acute Kidney Disease, Chronic Kidney Disease
Perioperative Nitric Oxide Prevents Acute Kidney Injury in Cardiac Surgery Patients With Chronic Kidney Disease
The protective nitric oxide (NO) effects are mediated by selective pulmonary vasodilation and improvement of arterial oxygenation in hypoxemic patients by reducing intrapulmonary shunting and improving ventilation-perfusion…
- Conditions
- Acute Kidney Disease, Chronic Kidney Disease, Cardiac Surgery, Cardiopulmonary Bypass
- Trial name
- DEFENDER (NCT05757557)
- Testing
- 80-ppm NO
- Where
- Russia
- Volunteers
- 136 people
- Sponsor
- Tomsk National Research Medical Center of the Russian Academy of Sciences
Post-Chemotherapy Peripheral Neuropathy
A Study on the Clinical Efficacy of Fumigation and Washing With Modified Astragalus and Cinnamon Twig Decoction With Five Herbs in the Treatment of Post-Chemotherapy Peripheral Neuropathy
This project aims to integrate the knowledge system of Traditional Chinese Medicine (TCM) pattern differentiation with TCM knowledge, combining TCM principles with modern Western pharmacology to fundamentally understand the…
- Trial name
- NCT07891403
- Testing
- Traditional Chinese Medicine Steam Bath
- Where
- China
- Volunteers
- 7 people
- Sponsor
- Emeishan Hospital of Traditional Chinese Medicine
Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)
A Phase 2b Study of Zagociguat in Patients With MELAS
PRIZM is a Phase 2b randomized, double-blind, placebo-controlled, 3-treatment, 2-period, crossover study evaluating the efficacy and safety of oral zagociguat 15 and 30 mg vs.
- Trial name
- PRIZM (NCT06402123)
- Testing
- zagociguat 15mg, zagociguat 30mg
- Where
- 20 sites in United States, Australia and 4 more
- Volunteers
- 43 people
- Sponsor
- Tisento Therapeutics
Graves Ophthalmopathy
Tocilizumab in Active Moderate-severe Graves' Orbitopathy
To treat patientis with active moderate-severe GO with the anti-IL6 receptor monoclonal antibody tocilizubam with the purpose of assesing the efficacy of therapy on active GO and on the proportion of patiens with inactivation and…
- Trial name
- TOGO (NCT04876534)
- Testing
- Tocilizumab 20 Mg/mL Intravenous Solution, MethylPREDNISolone Injectable Solution
- Where
- 4 sites in Italy
- Volunteers
- 56 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
FLT3 Gene Mutation Negative, FLT3 Internal Tandem Duplication Positive
Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
This phase I/II trial studies the side effects and best dose of quizartinib when given in combination with azacitidine or cytarabine in treating patients with acute myeloid leukemia or myelodysplastic syndrome that have come back…
- Conditions
- FLT3 Gene Mutation Negative, FLT3 Internal Tandem Duplication Positive, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia
- Trial name
- NCT01892371
- Testing
- Azacitidine, Cytarabine, Quizartinib
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- M.D. Anderson Cancer Center
Cognitive Impairment Associated With Schizophrenia (CIAS)
A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia
This is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) effects of 3 different dose regiments of KYN-5356 and placebo for 28 days.
- Trial name
- NCT07191483
- Testing
- KYN-5356 low dose, KYN-5356 Medium Dose, KYN-5356 High Dose
- Where
- 15 sites in United States
- Volunteers
- 149 people
- Sponsor
- Kynexis B.V.
Highly Sensitized Prospective Kidney Transplant Recipients
Daratumumab and Belatacept for Desensitization
Some kidney transplant candidates have a very low chance of getting a kidney transplant because their immune systems are "highly sensitized" to most kidney donors.
- Trial name
- ATTAIN (NCT04827979)
- Testing
- daratumumab, belatacept, Bone marrow aspiration
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Prostate Cancer (Adenocarcinoma)
68Ga-P16-093 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI
68Ga-P16-093 is a novel radiotracer targeting PSMA. In this study, we investigated the diagnostic efficacy of 68Ga-P16-093 PET imaging (PET/CT or PET/MRI) in patients with newly diagnosed, treatment-naive prostate cancer, and…
- Trial name
- NCT07209865
- Testing
- 68Ga-P16-093
- Where
- China
- Volunteers
- 82 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University